Clinical Trials Logo
  1. Home
  2. Healthy Volunteers
  3. NCT05012436
  4. Details
NCT05012436 Clinical Trial

A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects

Healthy Volunteer Clinical Trial

Official title:
A Study to Evaluate the Pharmacokinetics and Safety Following a Single Oral Dose of YHD1119 in Subjects With Renal Impairment and Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05012436
Other study ID # YHD1119-107
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 24, 2021
Est. completion date May 10, 2022

Study information
Verified date June 2022
Source Yuhan Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this trial is to compare the pharmacokinetic characteristics and safety of YHD1119(Pregabalin SR 75mg) and YHD1119(Pregabalin SR 150mg) in subjects with renal impairment and healthy subjects. YHD1119 is sustained-release (SR) formulation which is made by Yuhan Corporation. Primary endpoints are Cmax and AUClast and secondary endpoints are AUCinf,Tmax, t1/2, CL/F and V/F.

Recruitment information / eligibility
Status Completed
Enrollment 16
Est. completion date May 10, 2022
Est. primary completion date May 10, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 75 Years
Eligibility Inclusion Criteria: - 19~75 years old, healthy volunteers and renal impairments - eGFR >= 60mL/min/1.73m2 - 60 mL/min/1.73m2 > eGFR >= 30mL/min/1.73m2 - written informed consent Exclusion Criteria: - AST or ALT > 1.5 * Upper normal range - Total bilirubin > 1.5 * Upper normal range - Blood CPK > 1.5 * Upper normal range - Total Cholesterol >1.5 * Upper normal range - Woman who is pregnant or lactating - Patients who are difficult to participate in cinical trials judged by Investigators - have participated in other clinical trials within 180 days before IP intake

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• YHD1119 75mg
A single oral dose

Locations
Country Name City State
Korea, Republic of CHA Bundang Medical Center, CHA University Gyeonggi-do
Korea, Republic of The Catholic University of Korea, Seoul St. Mary's Hospital Seoul

Sponsors (1)
Lead Sponsor Collaborator
Yuhan Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Cmax 0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour
Primary AUClast 0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour
Secondary AUCinf 0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour
Secondary Tmax 0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour
Secondary t1/2 0,1,2,3,4,5,6,8,10,12,14,24,48,72hour
Secondary CL/F 0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour
Secondary V/F 0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour
See also
  Status Clinical Trial Phase
Completed NCT06326723 - Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects Phase 1
Recruiting NCT00001367 - Diagnosis and History Study of Patients With Different Neurological Conditions
Completed NCT02699710 - Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects Phase 1
Completed NCT02231892 - Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study N/A
Not yet recruiting NCT06441916 - Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions Phase 1
Completed NCT03771586 - A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects Phase 1
Not yet recruiting NCT06337422 - Bioequivalence Study of Generic Celecoxib 200 mg Capsules Phase 1
Completed NCT03302182 - Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects Phase 1
Completed NCT05049343 - Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants Phase 1
Recruiting NCT01629108 - Normal Values in Hearing and Balance Testing
Completed NCT02947854 - Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant Phase 1
Completed NCT02534870 - Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects Phase 1
Completed NCT02224053 - Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers Phase 1
Completed NCT01711762 - A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers Phase 1
Completed NCT01676584 - A Study of Single Dose RO6811135 in Healthy Volunteers Phase 1
Completed NCT01684891 - A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers Phase 1
Completed NCT01697436 - A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets Phase 1
Completed NCT01433575 - A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers Phase 1
Completed NCT02547259 - Influence of Emotion in a Test Run Forgetfulness N/A
Completed NCT01579149 - A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent Phase 1